Q85.02
BillableNeurofibromatosis, type 2
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is Q85.02 an HCC code?
Yes. Q85.02 maps to Melanoma and Other Skin Cancers under the CMS-HCC V28 risk adjustment model (and Breast, Prostate, and Other Cancers and Tumors under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for Q85.02
For Q85.02 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed Q85.02 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
Q85.02 is the ICD-10-CM diagnosis code for neurofibromatosis, type 2. Neurofibromatosis type 2 is an inherited genetic disorder characterized by benign tumors on the hearing nerves and other nerve tissues, often causing hearing loss. Q85.02 sits in the ICD-10-CM chapter for congenital malformations, deformations, chromosomal abnormalities, and genetic disorders (q00-qa0), within the section covering other congenital malformations (q80-q89).
Under the CMS-HCC V28 risk adjustment model, Q85.02 maps to Melanoma and Other Skin Cancers (HCC 23) with a community, non-dual, aged base RAF weight of 0.251. Under the older CMS-HCC V24 model, Q85.02 maps to Breast, Prostate, and Other Cancers and Tumors (HCC 12) with a community, non-dual, aged base RAF weight of 0.150. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
NF2 typically presents with bilateral acoustic neuromas; document hearing loss and other neurological manifestations. Because Q85.02 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for Q85.02 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •NF2 typically presents with bilateral acoustic neuromas; document hearing loss and other neurological manifestations
- •Link this code with codes for associated conditions like hearing impairment or neurological complications
Clinical Significance
Neurofibromatosis type 2 is a rare but serious genetic disorder characterized by bilateral acoustic neuromas with high risk of hearing loss and other central nervous system tumors, requiring specialized neurosurgical and audiological management. The condition often presents in young adults and can be life-altering, making early diagnosis and intervention crucial for preserving function.
Documentation Requirements
- ✓Bilateral vestibular schwannomas (acoustic neuromas)
- ✓Unilateral vestibular schwannoma plus family history of NF2
- ✓Multiple meningiomas plus unilateral vestibular schwannoma
- ✓Genetic testing confirming NF2 gene mutation
- ✓Audiological assessment documentation
- ✓MRI findings of central nervous system tumors
- ✓Family history and genetic counseling records